Zymeworks Submits ZW25 Phase 1 Clinical Study Findings Abstract for ASCO 2017

February 23, 2017

Vancouver, Canada, (February 23, 2017) – Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that it has submitted an abstract for the 2017 American Society of Clinical Oncology (“ASCO”) annual meeting that contains preliminary Phase 1 data from the ZW25 Phase 1 clinical trial for treatment of HER2-expressing tumors.

“Two of the three cohorts from the dose escalation portion of the ZW25 Phase 1 clinical trial have been fully enrolled and preliminary data has been received for those patients,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “ZW25 is being evaluated for safety, as well as preliminary anti-tumor activity, and we are pleased to have been able to compile these results and submit them for presentation at this year’s ASCO annual meeting.”

The 2017 ASCO annual meeting will be held June 2nd through June 6th in Chicago, Illinois. The ASCO annual meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies and ongoing developments in the field of oncology. Abstracts will be released to the public on May 17th at 5:00 P.M. EDT and made available on ASCO’s website.

About ZW25

ZW25 is Zymeworks’ lead product candidate currently being evaluated in an adaptive Phase 1 clinical trial in the United States, based on our Azymetric platform. It is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and enhanced effector function. These combined mechanisms of action have led to significant anti-tumor activity in preclinical models. We are developing ZW25 as a best-in-class HER2-targeting antibody intended as a treatment option for patients with any solid tumor that expresses HER2.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial.  Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies. 

Investor Inquiries:

David Matousek
Senior Manager, Investor Relations & Corporate Communications
(604) 678-1388
ir@zymeworks.com

Stephanie Carrington
ICR Inc.
(646) 277-1282
stephanie.carrington@icrinc.comStephanie Carrington